Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1-Reference-Cited by-同舟云学术

Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1

Published:2022-06 Issue:6 Volume:25 Page:1010-1017
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Vadgama Sachin,Mann Jess,Bashir Zahid,Spooner Clare,Collins Graham P.,Bullement Ash

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference25 articles.

1. CAR-T cell therapy: personalised immunotherapy for cancer;Chaplin;Prescriber,2018

2. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial;Locke;Lancet Oncol,2019

4. CD19-loss with preservation of other B-cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel;Neelapu;Blood,2019

5. Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel);Jacobson;Blood,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States;Value in Health;2024-08

2. Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know;PharmacoEconomics;2024-07-05

3. Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial;Future Oncology;2024-06-05

4. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States;Journal of Medical Economics;2023-12-19

5. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma;Annals of Internal Medicine;2023-12